Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma

Autor: Alessandra Lopes, Kevin Vanvarenberg, Špela Kos, Sophie Lucas, Didier Colau, Benoît Van den Eynde, Véronique Préat, Gaëlle Vandermeulen

Publikováno v: Scientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)

Abstract DNA vaccination against cancer has become a promising strategy for inducing a specific and long-lasting antitumor immunity. However, DNA vaccines fail to generate potent immune responses when used as a single therapy. To enhance their activi

Externí odkaz: https://doaj.org/article/8a185f7e782e4e90bd9cd7722f8cbb6c

Using First-Passage Times to Analyze Tumor Growth Delay

Autor: Patricia Román-Román, Sergio Román-Román, Juan José Serrano-Pérez, Francisco Torres-Ruiz

Publikováno v: Mathematics, Vol 9, Iss 6, p 642 (2021)

A central aspect of in vivo experiments with anticancer therapies is the comparison of the effect of different therapies, or doses of the same therapeutic agent, on tumor growth. One of the most popular clinical endpoints is tumor growth delay, which

Externí odkaz: https://doaj.org/article/f5b32ffac5d34b34835bd32fecafa2f1

Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents

Autor: Patricia Switten Nielsen, Pernille B. Elming, Thomas Wittenborn, Michael R. Horsman

Publikováno v: International Journal of Molecular Sciences
Volume 21
Issue 13
Horsman, M R, Wittenborn, T R, Nielsen, P S & Elming, P B 2020, ' Tumors resistant to checkpoint inhibitors can become sensitive after treatment with vascular disrupting agents ', International Journal of Molecular Sciences, vol. 21, no. 13, 4778, pp. 1-14 . https://doi.org/10.3390/ijms21134778
International Journal of Molecular Sciences, Vol 21, Iss 4778, p 4778 (2020)

Immune therapy improves cancer outcomes, yet many patients do not respond. This pre-clinical study investigated whether vascular disrupting agents (VDAs) could convert an immune unresponsive tumor into a responder. CDF1 mice, with 200 mm3 C3H mammary

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45e94edc3eb03b48ba75e0ae2b464494

Beyond The T/C Ratio: Old And New Anticancer Activity Scores In Vivo

Autor: Paolo, Ubezio

Publikováno v: Cancer Management and Research

Assessing the efficacy of anticancer agents in animal models remains a necessary step in the development of new treatment options and plays an important role in their optimization and comparison. Often, however, interpretation of the results is flawe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9d8542710f5d1197faf933ad389861c0
https://pubmed.ncbi.nlm.nih.gov/31572007